Lupin launches budesonide inhalation suspension

Pharma major Lupin informed the bourses that it has launched Budesonide Inhalation Suspension, 0.5 mg/2 mL Single-Dose Ampules in the US market on Wednesday. The company had earlier received USFDA approval for the suspension.

Budesonide Inhalation Suspension is used to control and avoid symptoms (wheezing and shortness of breath) caused by asthma. The said medicine had a projected market size of US$385.4 million in the 12-month period ending March 2019 in the US market.

Lupin is engaged in developing and delivering branded and generic formulations. It also produces biotechnology products and APIs, globally. It is also a major player in Cardiovascular, Diabetology, Asthma, Pediatric, CNS, Gl, Anti-Infective and NSAID space.

The company’s FY18 revenue mix comprises of Domestic formulation (26 per cent) and Export formulation (65 per cent). Its geographical mix comprises of US (37 per cent), Japan (13 per cent) and Europe (4 per cent).

On Wednesday, the stock opened at Rs. 756.90 per share and made an intraday low of Rs. 741.55 and finally closed at Rs. 756.35 on the BSE. The stock had hit its 52-week high of Rs. 986 on September 10, 2018 and its 52-week low of Rs. 720.40 on March 28, 2019 on the BSE.